MGI and Karolinska's Centre for Translational Microbiome Research will work together to investigate the role of the microbiome in human health.
The complaint, filed yesterday, alleges that Illumina's two-channel sequencing systems infringe Complete Genomics' US Patent No. 9,222,132.
The lawsuit follows a similar one that Illumina filed earlier this year in Germany against Latvia MGI Tech, another subsidiary of BGI Group.
The BGI Group subsidiary said it plans to strengthen its R&D and instrument production, targeting a global sequencing market it expects to grow to $12.45 billion in 2022.
Both teams had sequencing data generated at BGI and said that going forward, it would be important to validate the technology outside of BGI.
The suit alleges that BGI's sequencing products and reagents infringe a European patent held by Illumina.
At the AGBT conference, MGI Tech showcased its technologies, while a Sanger Institute researcher presented results from a comparison between BGI and Illumina data.
The Shenzhen, China-based BGI subsidiary plans to expand its business to the United Arab Emirates, Qatar, Saudi Arabia, and other countries.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
Paragon and MGI Tech — a unit of BGI — have signed a distribution deal for certain of their respective next-generation sequencing panels and sample prep products.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.